Advertisement
Organisation › Details
University of Texas System
Start | 2000-09-01 existent | |
Industry | science | |
City | n. a. | |
Address record changed: 2011-05-15 | ||
Basic data | Employees | n. a. |
Record changed: 2018-10-31 |
Advertisement
More documents for University of Texas System
- [1] ImmunOs Therapeutics AG. (5/24/23). "Press Release: ImmunOs Therapeutics Announces Initiation of Dosing in Phase 1 Trial of Lead Compound IOS-1002". Schlieren & Gaithersburg, MD....
- [2] ImmunOs Therapeutics AG. (4/25/23). "Press Release: ImmunOs Therapeutics Appoints Michael A. Curran, PhD, as Chairman of its Scientific Advisory Board". Schlieren & Gaithersburg, MD....
- [3] Affimed N.V.. (4/10/22). "Press Release: Affimed Presents Updated Clinical Data from Phase 1/2 Study of AFM13 Precomplexed with Cord Blood-Derived NK Cells at AACR Annual Meeting". Heidelberg....
- [4] NBE Therapeutics AG. (10/26/20). "Press Release: NBE-Therapeutics Commences First Clinical Study of Anti-ROR1 Antibody-Drug Conjugate for Patients with Solid Tumors". Basel....
- [5] Boehringer Ingelheim. (8/12/19). "Press Release: Boehringer Ingelheim and MD Anderson Form Unique Virtual Research and Development Center to Rapidly Advance New Cancer Therapies". Ingelheim....
- [6] Mologen AG. (11/12/18). "Press Release: Lefitolimod – First Clinical Data in Combination with a Checkpoint Inhibitor and further Preclinical Results Presented at SITC 2018". Berlin....
- [7] Bruker Corporation. (5/21/18). "Press Release: Bruker Introduces the New Tracer 5g Handheld XRF Spectrometer". Salt Lake City, UT....
- [8] Heidelberg Pharma AG. (3/1/18). "Press Release: Heidelberg Pharma Signs License Agreement with The University of Texas MD Anderson Cancer Center". Ladenburg....
- [9] Immatics Biotechnologies GmbH. (9/28/17). "Press Release: Immatics Initiates the First Phase I Clinical Trial of its Unique ACTengine Approach in Patients with Advanced Solid Cancers". Houston, TX & Tübingen....
- [10] Immatics Biotechnologies GmbH. (8/21/17). "Press Release: Immatics Initiates Personalized Adoptive Cellular Therapy in Patients with Relapsed And/Or Refractory Solid Cancers Using Its Pioneering Target Warehouse". Houston, TX & Tübingen....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)
Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)
Advertisement
» top